Exploring synthetic lethal network for the precision treatment of clear cell renal cell carcinoma

The emerging targeted therapies have revolutionized the treatment of advanced clear cell renal cell carcinoma (ccRCC) over the past 15 years. Nevertheless, lack of personalized treatment limits the development of effective clinical guidelines and improvement of patient prognosis. In this study, large-scale genomic profiles from ccRCC cohorts were explored for integrative analysis. A credible method was developed to identify synthetic lethality (SL) pairs and a list of 72 candidate pairs was determined, which might be utilized to selectively eliminate tumors with genetic aberrations using SL partners of specific mutations. Further analysis identified BRD4 and PRKDC as novel medical targets for patients with BAP1 mutations. After mapping these target genes to the comprehensive drug datasets, two agents (BI-2536 and PI-103) were found to have considerable therapeutic potentials in the BAP1 mutant tumors. Overall, our findings provided insight into the overview of ccRCC mutation patterns and offered novel opportunities for improving individualized cancer treatment.

Automated summary

In this study, large-scale genomic profiles from ccRCC cohorts were analyzed to identify synthetic lethality pairs and potential medical targets. BRD4 and PRKDC were identified as novel targets for patients with BAP1 mutations, and two drugs, BI-2536 and PI-103, were found to have therapeutic potential for BAP1 mutant tumors. Overall, this study provides insight into ccRCC mutation patterns and offers new opportunities for personalized cancer treatment.